Alkermes Considers Avadel Pharmaceuticals' Recent Announcement
Alkermes plc (Nasdaq: ALKS) has taken note of Avadel Pharmaceuticals plc's recent disclosure about a potential acquisition offer from H. Lundbeck A/S. This situation has prompted Alkermes to thoroughly evaluate its next steps along with its advisory team.
The announcement by Avadel presents a proposal involving the acquisition of its outstanding shares by Lundbeck. This news has sparked strategic discussions within Alkermes as they weigh their options in the evolving landscape of the pharmaceutical industry.
Per the existing Transaction Agreement between Alkermes and Avadel, there are specific protocols that must be followed before Avadel can engage in any further commitments regarding the proposed offer. Avadel is bound by certain conditions that necessitate them to consult with Alkermes prior to making decisions that could impact the agreed-upon terms.
Understanding the Transaction Agreement
Under the terms specified in the Transaction Agreement, Avadel is not permitted to terminate the agreement to pursue a superior proposal without meeting certain obligations. This includes a fiduciary duty to assess if not pursuing such an action aligns with their responsibilities. Moreover, Avadel must provide written notification to Alkermes five business days prior to any decision to change direction, ensuring a period for negotiation and dialogue concerning the transaction.
This transparent communication is vital as it maintains the integrity of their ongoing partnership while allowing both parties to explore their interests responsibly.
The Importance of Staying Informed
Alkermes is committed to keeping stakeholders informed as developments unfold. The board's deliberations will be accompanied by timely announcements, keeping investors and the public abreast of any significant changes related to this situation.
Investor Relations and Media Contact Information
Alkermes remains receptive to inquiries from both investors and media representatives regarding this matter. For those interested in further details, inquiries can be directed to:
Alkermes Investor Relations
Sandy Coombs
Phone: +1 781 609 6377
Alkermes Media Relations
Katie Joyce
Phone: +1 781 249 8927
Financial Advisors for Alkermes
J.P. Morgan is providing exclusive financial advisory services for Alkermes in relation to this transaction and will not consider any other person as a client regarding these matters. J.P. Morgan maintains its commitment to ensuring high levels of service and protection for Alkermes throughout this process.
Responsibility for Information
Alkermes takes full responsibility for the accuracy of the information shared in this communication. The directors are diligent in ensuring that the information disclosed is factual and complete, aligning with the needs and expectations of stakeholders.
Looking Ahead
This announcement serves simply as an informative update and does not constitute an offer or invitation to purchase securities. Given the possible legal implications in various jurisdictions, it is crucial for interested parties to stay informed and navigate their inquiries with care.
Frequently Asked Questions
What did Avadel Pharmaceuticals announce?
Avadel announced a potential acquisition offer from H. Lundbeck A/S aimed at its shareholders.
How is Alkermes responding to this announcement?
Alkermes is carefully considering its options along with its advisory team to navigate the potential impact of the announcement.
What are the terms of the Transaction Agreement?
The terms specify that Avadel cannot terminate the agreement without fulfilling certain obligations and notifying Alkermes.
Who can I contact for more information?
For inquiries, contact Sandy Coombs for investors or Katie Joyce for media matters.
What role does J.P. Morgan play in this situation?
J.P. Morgan is acting exclusively as the financial advisor for Alkermes regarding the developments in this announcement.
